April 25, 2018
WELLESLEY, Mass., April 25, 2018 – Increasing adoption of circulating tumor cell technologies (CTC), the increasing incidence of cancer and reimbursement support are driving growth within the global market. In a new report Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets, BCC Research estimates that this industry will reach $4.6 billion in 2017 and $10.3 billion in 2022, with a compound annual growth rate (CAGR) of 17.6%.
CTCs can help evaluate cancer progression to gauge patient prognosis as well as their response to current cancer therapies, proving beneficial to patient health. Many technologies for the detection, characterization and analysis of CTCs are garnering significant attention. Currently, the United States and Europe are the major geographic markets for CTC technology.
Menarini-Silicon Biosystems, which owns Johnson & Johnson’s Veridex division, is the only company with FDA approval in the CTC prognostics area. The company’s test kit is useful for testing the prognosis of patients suffering from metastatic stage in breast cancer, prostate cancer and colorectal cancers. Many companies have products in clinical trials and are expected to compete in the next few years with newer and better products.
“One of the most important drivers for the excipient industry is the global demand for pharmaceutical products,” said Robert G. Hunter, BCC Research senior editor, healthcare. “This includes mature products and generics, as well as novel drugs for orphan and new emerging diseases.”
Editors/reporters requesting analyst interviews should contact firstname.lastname@example.org.
Qualified members of the press can also request permission to access the BCC Research library.
Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets( PHM153B )
Publish Date: Apr 2018
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49 Walnut Park, Building 2, Wellesley, MA 02481, Telephone: 866-285-7215; Email: email@example.com as the source and publisher. Thank you.